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p = 0.035), the other SNPs showed trends. Stratified for 
received treatment, the effect was only present in methyl-
prednisolone treated patients. Mutant allele carriage sig-
nificantly decreased functionality of P-gp in B cells, though 
had a smaller impact in other PBMC subtypes. Carriage of 
a MDR1 SNP was related to a response to methylpredniso-
lone in this study, which his suggests that RA-patients car-
rying wild-type alleles might benefit from P-gp inhibition 
or administration of glucocorticoid analogues that are non-
P-gp substrates.
Keywords Multidrug resistance · MDR1 · Rheumatoid 
Arthritis · Glucocorticoids · Polymorphisms
Introduction
Rheumatoid arthritis (RA) is a chronic, disabling disease 
that mainly affects the synovial joints. Glucocorticoids 
Abstract A substantial proportion of rheumatoid arthritis 
(RA)-patients experience an insufficient response to gluco-
corticoids, an important therapeutic agent in RA. The mul-
tidrug-resistance 1 (MDR1) gene product P-glycoprotein 
(P-gp) is an efflux pump that actively transports substrates, 
such as glucocorticoids, out of the cell. We investigated 
if the variation in response might be explained by single-
nucleotide polymorphisms (SNPs) in the MDR1 gene. 
RA-patients treated with intravenous methylprednisolone 
pulses (n = 18) or oral prednisone/prednisolone (n = 22) 
were included in a prospective cohort, and clinical response 
was measured after 5 and 30  days, respectively. The 
C1236T, G2677A/T, and C3435T SNPs were determined, 
and the functionality of P-gp was assessed by flow cytom-
etry (Rhodamine efflux assay). Carriage of the G2677A/T 
SNP was significantly associated with response (OR = 6.18, 
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(GC) compose a class of drugs that have an important place 
in RA treatment [1]; however, a substantial proportion of 
patients experiences insufficient response.
The multidrug-resistance 1 (MDR1) gene product, the 
P-glycoprotein (P-gp), is an efflux pump that actively trans-
ports substrates, such as drugs, out of the cell. The ability 
to regulate intracellular substrate concentration depends on 
both the expression and the functionality (i.e., recognition 
of substrates and transport effectiveness) of P-gp [2]. In 
treatment refractory RA, P-gp overexpression in lympho-
cytes is believed to play a substantial role, as it has been 
shown that overexpression reduces intracellular concentra-
tions of immunosuppressants that are P-gp substrates [3]. 
Single-nucleotide polymorphisms (SNPs) have been linked 
to P-gp activity and are suspected to influence inter-indi-
vidual variation in response to certain treatments [4, 5]. 
Because GCs are known P-gp substrates [6, 7], differences 
in GC response might be explained by carriage of poly-
morphisms in the MDR1 gene. We, therefore, explored the 
possibility that carriers of mutant alleles in the MDR1 gene 




RA-patients treated with GCs at our department of Rheu-
matology were included in a prospective cohort. Patients 
eligible for intravenous (IV) GC pulse treatment according 
to their treating rheumatologist were given three doses of 
1000 mg IV methylprednisolone on alternate days, as this 
approach has been proven to be quick, effective (in  short 
and long term), and safe [8–10]. RA-patients with an indi-
cation for oral GC treatment were treated with prednisone 
or prednisolone doses between 7.5 and 10 mg for at least 
1  month. Based on our clinical experience and the previ-
ous research on IV pulse treatment [8], the optimal time 
point to measure (maximum) treatment effect was consid-
ered 5 days after start. Treatment response in orally treated 
patients was assessed at day 30 which was considered suffi-
cient as a response as early as two weeks is already a strong 
indicator of the long-term clinical outcome [11]. DAS28 
response was evaluated according to the European league 
against Rheumatism (EULAR) response criteria [12]. 
EULAR good response, i.e., a DAS ≥ 1.2 and DAS28 < 3.2, 
was compared to the combination of moderate and non-
response considering the intensity of the treatment, espe-
cially in the IV arm.
Whole blood was collected in Li-Heparin tubes. Periph-
eral blood mononuclear cells (PBMCs) were isolated and 
stored in liquid nitrogen until use. The study was approved 
by the medical ethics committee of the University Medical 
Center Utrecht and was conducted in accordance with the 
Helsinki Declaration. All patients signed informed consent.
Genotyping of MDR1
Genomic DNA was extracted from  105 PBMCs using 
QIAamp DNA blood mini kit (Cat. No 51104, Quigen, 
Hilden, Germany) according to manufacturer’s instruc-
tions. C1236T (rs1128503), G2677A/T (rs2032582), and 
C3435T (rs1045642) SNPs were genotyped using TaqMan 
allelic discrimination assay technology (Applied Biosys-
tems, Foster City, California, USA) on a QuantStudio 7 
Flex Real-Time PCR System (Thermo Fisher Scientific 
Inc, Foster City, California, USA), according to the manu-
facturer’s instructions. The analyses were run in duplicate. 
The mutant allele frequency of the study cohort (observed 
frequency) was compared with the Central European 
occurrence (expected allele frequency, derived from 1000 
Genomes catalog [13]).
Functionality of P-gp
The functionality of P-gp was assessed by flow cytom-
etry, using a Rhodamine efflux assay. 4.0 × 105 cryo-
preserved PBMCs were incubated with Rhodamine 123 
(Sigma–Aldrich, St. Louis, USA) at a final concentration of 
1 μg/ml for 30 min at 4 °C and washed twice. After divid-
ing cells in two wells, they were incubated in the pres-
ence (control) or absence of the MDR1-inhibitor Elacridar 
(Astrazeneca, Mölndal, Sweden). The cells were stained 
with antibodies to determine subsets of PBMCs: CD3, 
CD4, CD8, CD14, CD16, CD19, CD196, and CD56 (all 
BD Bioscience, San Jose, USA). Flow cytometry was 
performed on a four laser LSR Fortessa (BD Bioscience, 
San Jose, USA) and samples were analyzed using FlowJo 
(Tree Star Inc. Ashland, USA). Only baseline samples (i.e., 
before start of therapy) with a clear FSC vs SSC profile 
containing living PBMCs were used for data analysis. As 
additive test for viability and proper labeling with Rho-
damine 123, all samples were excluded that had >5% low 
Rhodamine 123 containing cells in the elacridar treated 
sample. After gating of living cells in the FSC vs SSC plot, 
duplicates and cell-aggregates were removed using FSC-A 
vs FSC-H plot. The frequency of cells effluxing Rhodamine 
123 in the uninhibited samples was used as a value for 
transport functionality.
Statistical analysis
Associations between each SNP and patient’s response 
were analyzed using logistic regression models, in which 
each investigated SNP was tested while  adjusted for 
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treatment received (IV/oral). SNPs were first analyzed in 
a dominant model in which the SNP was coded dichoto-
mously (wild-type/mutant allele carrier) and subsequently 
in an additive model [linear covariate coded: zero mutant 
alleles (wild-type)/one mutant allele (heterozygous)/two 
mutant alleles (homozygous mutant)]. All analyses were 
performed in SPSS 21 (IBM Corp., Armonk, NY).
Results
Baseline characteristics of patients treated with IV meth-
ylprednisolone (n = 18) and oral prednisone/prednisolone 
(n = 22) are shown in Table  1. There were no differences 
between the cohorts, apart from a higher DAS28 at baseline 
in line with the difference in clinical indication for the two 
treatment regimens.
Since concomitantly used disease-modifying anti-rheu-
matic drugs (DMARDs) might confound the investigated 
relationship of GCs and response, we additionally investi-
gated the distribution of concomitant DMARDs use among 
the responders and non-responders (Online Resource 1). 
However, no effect of any DMARD on (non-)response was 
seen.
Mutant allele frequencies
The observed allele frequency was lower than expected 
based on the general population; however, these differ-
ences did not reach statistical significance: 0.36 for T-allele 
of C1236T (0.43 expected, binominal test of propor-
tion p = 0.10), 0.37 for A or T-allele of G2677AT (0.44 
expected, p = 0.11), and 0.50 for T-allele C3435T (0.57 
expected, p = 0.11).
Genotype and response to GC therapy
The dominant model revealed an OR of 6.18 for G2677A/T 
polymorphism carriers and a trend for the other SNPs 
(Table 2). In the additive model, a trend for all SNPs and 
mutant allele carriers was found (data not shown). Strati-
fied for the received treatment, wild-type carriers for all 
SNP in the IV cohort failed to achieve response, whereas 
43–50% of the mutant allele carriers achieved a response 
(p = 0.05 for G2677A/T). For oral treatment, no differences 
in SNPs and response rates were observed.
Functionality of P-gp
Of the originally 40 samples, 18 had to be excluded for 
P-gp functionality testing due to viability <40% and an 
additional two as they were taken after therapy initiation. 
Mutant allele carriers of all three SNPs showed lower func-
tionality in B cells (p = 0.03), and for other cell sets, a small 
decrease in functionality was observed (all p > 0.10, Fig. 1).
Discussion
This study investigated the role of polymorphisms in the 
MDR1 gene in the response to IV and oral GC therapy 
in RA, and showed that the response to IV methylpred-
nisolone is significantly better in patients carrying the 
G2677A/T polymorphism compared to the wild-type car-
riers, with trends for the other SNPs. Mutant allele car-
riage for any MDR1 SNP was associated with a significant 
decreased P-gp functionality in B cells, whereas the impact 
on other PBMC subtypes was smaller but still present. 
Non-response to methylprednisolone might, therefore, be 
(partially) explained by the role of polymorphisms in the 
MDR1 gene and subsequent effect on P-gp activity.
Table 1  Baseline 
characteristics for intravenous 
and oral GC treated cohorts
p values were calculated by Fisher exact or t test for, respectively, dichotomous and continuous variables
AZA azathioprine, DAS28 disease activity score based on 28-joint count, DMARD disease-modifying anti-
rheumatic drugs, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, SSZ sulfasalazine
Item IV cohort (n = 18) Oral cohort (n = 22) p value
Female gender, n (%) 13 (72.2) 18 (81.8) 0.71
Age, mean (±SD) 61.4 (±17.7) 59.8 (±15.1) 0.76
DMARD naïve, n (%) 3 (16.7) 6 (27.3) 0.70
Biological use, n (%) 2 (11.1) 4 (18.2) 0.68
MTX use, n (%) 9 (50.0) 12 (54.5) 1.00
LEF use, n (%) 2 (11.1) 1 (4.5) 0.58
AZA use, n (%) 0 (0.0) 1 (4.5) 1.00
SSZ use, n (%) 1 (5.6) 1 (4.5) 1.00
HCQ use, n (%) 2 (11.1) 3 (13.6) 1.00
DAS28 Baseline, mean (±SD) 6.3 (±1.1) 5.2 (±1.5) 0.01
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The observed difference in effect of polymorphisms 
on the GC response in IV methylprednisolone compared 
to prednisone/prednisolone treated patients could be 
explained by two mechanisms. First, a profound differ-
ence in dependency on P-gp among GC analogues has been 
shown [14]. Methylprednisolone has the highest transport 
efficiency by P-gp of all GCs and thus is transported more 
efficiently than prednisolone (i.e. active component of 
prednisone). Consequently, an impaired function of P-gp 
due to a mutant allele exerts more impact in methylpred-
nisolone compared with prednisone/prednisolone treated 
patients, which is in line with our results. Second, different 
substrate concentrations might lead to different effects on 
(dys)function. Whereas at low dose therapy (oral cohort), 
substrate influx and P-gp excretion may be in equilibrium, 
a drastic increase in substrate concentration, such as in IV 
pulse treatment, could result in a relative dysfunctionality 
of P-gp. This hypothesis fits the observations from in vitro 
work demonstrating differences in functionality between 
wild-type and polymorphism carriers at high substrate con-
centration (2.6 µM [15] and 5.0 µM [4]) but not at lower 
substrate concentrations (0.4 µM [16]). In this study, a sub-
strate concentration of 2.6  µM was used, which showed 
lower efflux in B cells though smaller differences in other 
cell subsets.
Several other studies have focused on the relation of 
SNPs and response to GCs treatments in inflammatory 
diseases. Two studies investigated the C3435T polymor-
phism in RA and the effect on the combination therapy 
of methotrexate and GCs, which yielded better response 
Table 2  SNPs and clinical response to IV and oral GC treatment
Wild-type (for each respective allele) versus mutant allele carriers were compared in a logistic regression analysis corrected for treatment 
received. Per SNP the odds ratio (OR) and related p value are presented. In the subsequent columns, the absolute number of responders and non-
responders per treatment is shown for wild-type and mutant allele carriers, including the overall p value (Fisher exact test). For the G2677AT 
polymorphism, there was a significant association between mutant allele carriage and response, though this association was restricted to the IV 
treated patients. Trends for the other SNPs and response to IV treatment were seen
SNP Overall OR p value for OR Treatment Genotype Non-
response, n 
(%)
Response, n (%) p value
C1236T 1.96 0.35 IV CC (n = 5) 5 (100) 0 (0) 0.11
CT/TT (n = 13) 7 (54) 6 (46)
Oral CC (n = 9) 5 (56) 4 (44) 0.66
CT/TT (n = 13) 8 (62) 5 (39)
G2677A/T 6.18 0.04 IV GG (n = 6) 6 (100) 0 (0) 0.05
GT/TT (n = 12) 6 (50) 6 (50)
Oral GG (n = 8) 6 (75) 2 (25) 0.38
GT/GA/AT/TT (n = 14) 7 (50) 7 (50)
C3435T 1.69 0.51 IV CC (n = 3) 3 (100) 0 (0) 0.52
CT/TT (n = 15) 9 (60) 6 (40)
Oral CC (n = 7) 4 (57) 3 (43) 1.00
CT/TT (n = 15) 9 (60) 6 (40)
Fig. 1  Functionality of P-gp for different subsets of PBMCs in %. 
Shown are the mean values and the standard deviations between 
wild-type carriers for all SNPs (haplotype carriers, n = 5) and mutant 
allele carriers for any MDR1 SNP (n = 15). CCR6+ CD4+ cells 
include most of the Th17 cells and subpopulations of regulatory- and 
memory T cells expressing CCR6+. Mutant allele carriers showed 
a decreased functionality of B cells (t test, p = 0.03) and minor 
decreased functionality for other cells subsets (all p > 0.10)
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rates for C3435T mutant allele carriers [17, 18]. Carriers 
of the G2677AT polymorphism in immune thrombocy-
topenia (ITP) have a better response to oral GCs, whereas 
the carriage of mutant alleles for C1236T and C3435T did 
not correlate with response [19]. In inflammatory bowel 
diseases, G2677AT did not relate to response, but C1236T 
and C3435T did [20]. The differences in results among 
these studies can partially be explained by factors related to 
demographics, disease, treatment, and study design (includ-
ing statistical power of the different studies), and, therefore, 
do not exclude the possibility of a shared underlying path-
way related to one or more SNPs.
Our study has its limitations with respect to the num-
ber of patients that were included, resulting in a reduced 
power for detecting effects and hampering correction for 
multiple testing. Therefore, the analyses should be consid-
ered exploratory, and, until validated in a bigger cohort, the 
results should be interpreted in that context. It should 
also be noted that although GC therapy was the subject of 
our study and concomitant treatments were stable, there 
were—albeit not significant—differences in used concomi-
tant DMARDs between the cohorts and between respond-
ers and non-responders. Because of the low sample size, 
however, it was not possible to correct for these differences 
in multivariable analyses. In this study, the possibility of 
(extra-cytosolic) non-genomic effects to GC treatment 
was not considered. However, such effects are expected to 
appear more rapidly than 5/30 days and are, therefore, not 
likely to have influenced the observations. The chosen time 
intervals to evaluate the clinical response might have influ-
enced the magnitude of the observed response, yet, the time 
points were based on empirical observations and were con-
sidered clinically most relevant. Another limitation is the 
low viability of PBMCs after thawing, possibly related to 
factors, such as transport or the age of the cells. The dead 
cells could have disturbed the results of the functionality 
assay, which would explain the limited differences in P-gp 
functionality between the polymorphisms.
Our data suggest that RA-patients with wild-type poly-
morphisms could potentially benefit from concomitant 
MDR1-inhibition (such as by cyclosporine, tacrolimus, and 
hydroxychloroquine [3]), administration of GC analogues 
that are less sensitive to P-gp transport (or not a substrate 
for P-gp), or treatments that are not influenced by P-gp, 
e.g., extracellular acting treatments, such as tumor necrosis 
factor alpha inhibitors. Additional work needs to be under-
taken using larger patient cohorts to better clarify the asso-
ciation between MDR1 SNPs, P-gp activity and response 
to GCs.
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